Objective: The calcium-sensing receptor (CASR) is a key controller of calcium homeostasis by regulating parathyroid hormone (PTH) secretion and renal calcium reabsorption. CASR T888 is a protein kinase C (PKC) phosphorylation site in the receptor's intracellular domain that has previously been identified as a critical negative regulator of CASR downstream signaling in vitro, but whose importance in vivo is unknown. Case report: The proband presented with mild symptomatic hypocalcemia following treatment for nephrotic syndrome due to minimal change glomerulonephropathy. Laboratory tests revealed inappropriately normal PTH concentrations and relative hypercalciuria typical of autosomal dominant hypocalcemia. His asymptomatic father had similar laboratory test results. Design and methods: The CASR gene was sequenced. To investigate the molecular consequences of CASR T888M mutation, site-directed mutagenesis was used to modify the wild-type (wt)-CASR gene, with the resulting mutant being transfected transiently into HEK-293 cells. Results: A novel CASR missense mutation, T888M, was identified in both cases. The CASR T888M mutant exhibited enhanced sensitivity to extracellular calcium concentration, both for intracellular calcium ðCa 2C i Þ mobilization and for ERK phosphorylation, despite having unaltered levels of cell surface expression. Furthermore, CASR T888M elicited sustained Ca 2C i mobilization rather than high frequency Ca 2C i oscillations, and, unlike the wt-CASR, the response was resistant to acute inhibition by the PKC activator, phorbol 12-myristate 13-acetate. Conclusions: The clinical and functional data provide the first genotype-phenotype correlation for a mutation at T888, indicating its critical physiological importance in CASR signaling. Thus, CASR T888 represents a functionally important, inhibitory phosphorylation site that contributes to the control of PTH secretion.
Introduction
The calcium-sensing receptor (CASR; MIM C601199) is a G protein-coupled receptor that is a key controller of extracellular calcium ðCa 2C o Þ homeostasis. CASR is highly expressed in the chief cells of the parathyroid gland, but is also expressed in other tissues including the thyroid, kidney, gastrointestinal tract, and bone. Both loss-of-function and gain-of-function CASR mutations have been described (1) (2) (3) .
Heterozygous loss-of-function mutations generally result in familial hypocalciuric hypercalcemia, and homozygous mutations result in neonatal severe hyperparathyroidism. The former is characterized by mild and the latter by severe hypercalcemia, together with inappropriately normal or frankly elevated parathyroid hormone (PTH) concentrations (1) (2) (3) . Conversely, gain-of-function mutations resulting in impairment of PTH secretion and renal calcium and magnesium reabsorption manifest as autosomal dominant hypocalcemia (ADH) (1) (2) (3) . More than fifty activating mutations have been described to date. These are collated at www. casrdb.mcgill.ca, and have been the subject of recent reviews (4, 5) . Although often familial, de novo mutations are not uncommon, with one case study of 19 unrelated cases of isolated hypoparathyroidism identifying eight individuals with distinct CASR mutations (6) .
The phenotype of ADH is characterized by persistent hypocalcemia with clinical features that vary from asymptomatic through to asthenia, muscle cramps, paresthesia, carpopedal spasm, and even seizures, in combination with inappropriately low concentrations of PTH and relative hypercalciuria (2, 6) . While in the hypocalcemic range, the serum total corrected calcium is almost never !1.20 mmol/l, with other suggestive features being a PTH within the normal range (i.e. around 1.0-6.0 pmol/l), serum magnesium %0.70 mmol/l and a urine calcium:creatinine ratio O0.30 mmol/mmol (2) . Owing to the relative hypercalciuria, ADH is associated with an increased risk of nephrocalcinosis and renal impairment, particularly with the use of active vitamin D analogs (2, 6, 7) . 1,25-dihydroxyvitamin D (1,25(OH) 2 D) has been shown to up-regulate renal CASR expression, and increased expression of activated CASR may result in worsening hypercalciuria (8, 9) .
While most mutations responsible for ADH are located in the extracellular regions of the CASR, several are located in the intracellular domain where they may influence trafficking, surface expression, and receptor signaling rather than agonist binding. An intracellular CASR residue known to be critical for the control of CASR activity in vitro is the protein kinase C (PKC) phosphorylation site threonine-888 (10-15); however, the in vivo effects of mutations at this site have not been described previously. In this study, we describe a family with ADH due to a novel T888M missense mutation and thus demonstrate the importance of this residue to CASR signaling in vivo.
Case report
The proband was a 24-year-old Caucasian male who was referred for evaluation of hypocalcemia. Eight months previously, he had developed nephrotic syndrome due to biopsy-confirmed minimal change glomerulonephropathy that readily responded to prednisolone therapy. He had also been treated with calcium carbonate 1500 mg and cholecalciferol 1000 IU/day for osteoporosis prophylaxis. The treating nephrologist noted hypocalcemia after the proteinuria and hypoalbuminemia had resolved.
There was a history of intermittent muscle cramps and carpal spasms since childhood that had improved on one occasion following a short course of calcium and magnesium supplements. These symptoms recurred during his illness, but settled after calcium and cholecalciferol were started.
There was no history of neck trauma or surgery, hearing impairment, seizures, or febrile convulsions. There was no known family history of hypocalcemia. Examination was unremarkable apart from the presence of several psoriatic plaques consistent with a history of psoriasis from childhood.
Blood tests taken 2 years prior to his presentation with nephrotic syndrome showed that the total serum calcium corrected for albumin was low at 1.96 mmol/l (reference range 2.15-2.55), albumin was normal at 46 g/l (reference range 35-50), and phosphate was high at 1.80 mmol/l (reference range 0.81-1.45). No action had been taken at that time. Blood tests performed during the hypoalbuminemic period associated with the nephrotic syndrome (serum albumin !20 g/l) demonstrated apparently normal corrected calcium concentrations. However, the total corrected calcium concentration was clearly below the lower limit of normal (values between 1.97 and 2.18 mmol/l) once the serum albumin normalized.
Investigations performed following referral showed that serum-ionized calcium was low at 1.05 mmol/l (reference range 1.15-1.35), serum magnesium was normal at 0.9 mmol/l (reference range 0.7-1.1), intact PTH was inappropriately normal (4.7 pmol/l; reference range 1.0-7.0), 25-hydroxyvitamin D (25OHD) was normal (132 nmol/l; reference range 50-150), but 1,25(OH) 2 D was elevated (213 pmol/l; reference range 40-153). Similar results were obtained on a repeat blood test 6 days later. The elevated 1,25(OH) 2 D concentration was further investigated with chest X-ray and serum angiotensin-converting enzyme concentration, which were normal, and Quanti-FERON-TB Gold Assay for Mycobacterium tuberculosis, which was elevated. Subsequent serial morning sputum samples were negative for M. tuberculosis, and a tuberculin skin test was negative. Infectious disease review concluded that the patient had a minimal likelihood of M. tuberculosis infection, and a cause for the high 1,25(OH) 2 D level was not identified.
A random urinary calcium:creatinine ratio was 0.48 mmol/mmol (reference range !0.4 in normocalcemic individuals) with a paired corrected serum calcium of 2.18 mmol/l. On a subsequent 24-h urinary specimen, the calcium:creatinine ratio was 0.15 mmol/ mmol with a paired serum calcium of 2.00 mmol/l. Both samples were taken while the patient was taking calcium supplements.
Screening of relatives (father, mother, brother, and father's siblings), all of whom were asymptomatic, showed that the patient's father was also hypocalcemic, but not other family members. The father's serum total corrected calcium was 2.01 mmol/l and serum-ionized calcium was 1.06 mmol/l, with an inappropriately normal serum PTH of 1.5 pmol/l and high urinary calcium:creatinine ratio of 0.43 mmol/mmol. Serum phosphate (1.3 mmol/l), magnesium (0.9 mmol/l), and 25OHD (103 nmol/l) were normal. Unlike the index case, 1,25(OH) 2 D was normal (111 pmol/l). These findings led us to suspect the presence of a heterozygous gain-of-function mutation of the CASR in the proband and his father consistent with a diagnosis of ADH. Informed consent for further testing and publication of the findings was obtained.
Methods

Biochemical tests
Routine laboratory analytes were assayed on a Beckman Coulter UniCel DxI 800 analyzer (Beckman Coulter Diagnostics, Brea, CA, USA). Calcitonin and PTH were measured on a Siemens Immulite 2000 analyzer (Siemens Medical Solutions Diagnostics Ltd, Malvern, PA, USA). Serum 25OHD was measured with ultraperformance liquid chromatography followed by tandem mass spectrometry (16) , and serum 1,25(OH) 2 D was measured with an immunoassay (Diasorin, North Ryde, NSW, Australia).
PCR product amplification and sequencing
DNA sequencing of the CASR gene was performed on extracted genomic DNA with an automated sequencer (ABI Prism; Perkin-Elmer Corp., Wellesley, MA, USA) as previously described (17).
Site-directed mutagenesis and cell culture
The T888M mutation was introduced by site-directed mutagenesis using the QuikChange (Stratagene, Agilent Technologies, Stockport, Cheshire, UK) method with the wild-type (wt) human parathyroid CASR in pcDNA3.1 as the template. HEK-293 cells were transiently transfected (FuGENE-6, Roche Diagnostics) with wt-CASR or CASR T888M and grown on glass coverslips in DMEM containing 10% (v/v) heat-inactivated fetal bovine serum (Invitrogen Ltd).
Total cellular CASR protein expression
Protein expression was demonstrated by western blotting as described previously, using an anti-CASR mouse MAB (amino acids 214-235 of human CASR; Affinity Bioreagents, Golden, CO, USA) (18, 19) . Briefly, cells were lysed in detergent-containing buffer supplemented with protease inhibitors and N-ethylmaleimide (1 mM), the lysate was centrifuged at 10 000 g (10 min, 4 8C), and the supernatant was solubilized in Laemmli buffer at 65 8C (3 min).
Intracellular calcium assay
CASR-induced changes in intracellular calcium ðCa 2C i Þ concentration were measured by epifluorescence microscopy as described previously (11, 12) using cells loaded with Fura-2 (Invitrogen). CASR-transfected cells were then incubated at room temperature in Experimental Buffer (20 mM HEPES (pH 7.4), 125 mM NaCl, 4 mM KCl, 0.5 mM CaCl 2 , 0.5 mM MgCl 2 , and 5.5 mM glucose) and exposed to increasing 
Cell surface expression
HEK-293 cells were transfected transiently with FLAGtagged (extracellular) CASR constructs. After 48 h, the cells were incubated with mouse monoclonal DDDDK tag antibody (G10; 1 mg/ml; Abcam, Sapphire Bioscience, Waterloo, Australia) in DMEM (10% fetal bovine serum (FBS)) for 2 h (4 8C with gentle rocking), and then washed and collected with ice-cold PBS and pelleted by centrifugation. Cells were then incubated with HRP-conjugated goat anti-mouse IgG antibody (1:5000; Sigma-Aldrich) in DMEM (10% FBS) for 1 h (4 8C with vigorous shaking). Cells were pelleted and washed as before and then incubated with 3,3 0 ,5,5 0tetramethylbenzidine (Sigma-Aldrich) for 20 min (in the dark with rocking), and the reaction was then stopped with an equal volume of 1.0 M HCl. Cells were pelleted, and then the absorbances of the supernatants were read in triplicate at 450 nm. Absorbances were corrected for background using an untransfected control and expressed as percentages of the cell surface expression of a wt control.
ERK phosphorylation
HEK-293 cells transfected transiently with CASR were assayed for ERK phosphorylation as previously described (19) . Briefly, cells were exposed to buffer containing various Ca 2C o concentrations at 37 8C for 10 min (or to 4 mM Ca 2C o for various time points up to 20 min) prior to lysis on ice in RIPA buffer supplemented with protease and phosphatase inhibitors. ERK phosphorylation was then determined by semi-quantitative immunoblotting using a phospho-specific antibody (Pierce, Fisher Scientific UK Ltd, Loughborough, UK).
Presentation of data and statistical analysis
The data are presented as meansGS.E.M., and statistical significance between datasets was determined by Student's unpaired or paired t-test (GraphPad Prism, La Jolla, CA, USA).
Results
Sequence analysis of exon 7 of the CASR genomic DNA in both the proband and his father revealed a heterozygous substitution of cytosine with thymidine at position 2663 (CASR:c.[2663COT]) ( Fig. 1 ). This mutation was predicted by PolyPhen (prediction of functional effect of human nsSNPs; http://genetics. bwh.harvard.edu/pph/) to have a position-specific independent counts (PSIC) score of 1.711, and modeling of the effect on the amino acid sequence of the CASR protein predicted a substitution of methionine for threonine at position 888 (p.T888M) that would abolish a major intracellular PKC phosphorylation site (12) .
Functional characterization of the CASR T888M mutation in HEK-293 cells
To investigate the functional consequence of the CASR T888M mutation in vitro, the mutation was recapitulated by mutating the wt-CASR cDNA. CASR T888M exhibited an apparent increase in Ca 2C o sensitivity relative to wt-CASR, and the EC 50 for Ca 2C o decreased significantly ( Fig. 2; wt, 3 .0G0.1 mM; T888M, 2.5G0.2 mM; P!0.05 by unpaired t-test of log EC 50 values). Western blotting revealed similar expression of protein bands consistent with the wellrecognized 140 kDa core-glycosylated and 160 kDa mature receptors (7, (12) (13) (14) (15) 20) in both sets of transfected cells (Fig. 2C ). In addition, there was no difference in cell surface expression between wt-CASR (100G6.4%) and CASR T888M (93.9G4.9%) FLAGtagged constructs in their respective extracellular domains.
Next, to investigate the consequence of the T888M mutation on the recognized inhibitory effect of phorbol ester treatment, wt-CASR-and CASR T888M -transfected cells were exposed to raised Ca 2C o concentration (4 mM) in the absence and then in the presence of 1 mM phorbol 12-myristate 13-acetate (PMA), a PKC stimulator. For wt-CASR, high Ca 2C o concentration induced rapid Ca 2C i oscillations that were abolished within 2 min of PMA cotreatment (Fig. 3A ; in the absence of PMA, Ca 2C i oscillations continued for at least 10 min (12)). In contrast, CASR T888M elicited mostly sustained Ca 2C i mobilization that exhibited a time-dependent decay and resistance to PMA-induced inhibition (Fig. 3B) . Finally, the apparent increase in Ca 2C o sensitivity seen with CASR T888M with respect to Ca 2C i mobilization (Fig. 2) was also observed in experiments examining the effect of CASR activation on ERK phosphorylation ( Fig. 4; WT 
Discussion
ADH in humans is a well-recognized consequence of activating mutations of the CASR, and a similar phenotype has been reported in the Nuf mouse, which is heterozygous for the CASR activating mutation L723Q (21) . ADH is typically associated with increased Ca 2C o sensitivity either from enhanced coupling between the receptor's extracellular Ca 2C -binding domains and intracellular signaling domains, or from enhanced trafficking and surface expression (1) . The findings reported here demonstrate that ADH can also arise when an inbuilt mechanism that uncouples the receptor from its intracellular signaling pathways is irreversibly disabled.
It has been shown previously that PTH secretion is increased by PKC activation in parathyroid cells exposed to moderate or high Ca 2C o concentrations that would otherwise suppress PTH secretion (22) (23) (24) (25) (26) (27) . Cloning of the CASR revealed PKC consensus sequences in its intracellular domain, and it was proposed that phosphorylation of one or more of these sites might uncouple the CASR from its downstream signaling pathway, thereby disinhibiting PTH secretion (28) .
Of the five predicted PKC consensus sites in the human CASR C-terminus, T888 is functionally the most important in terms of phosphatidylinositol phospholipase C-dependent signaling in HEK-293 cells (13) . Bai et al. (13) demonstrated this using site-directed mutagenesis of the five sites, finding that mutation of T888 substantially altered receptor sensitivity and responsiveness to PMA. In contrast, mutation of PKC sites T646 and S794 in the intracellular loops was without effect, and mutation of the intracellular domain residues S895 or S915 had only a small effect on receptor sensitivity and responsiveness to PMA (9) . Specifically, mutation of CASR T888 to certain nonphosphorylatable residues (e.g. alanine and valine) increased apparent Ca 2C o sensitivity of the CASR, whereas phosphomimetic mutations (e.g. aspartate and glutamate) attenuated Ca 2C sensitivity (13, 14) . Rather than altering Ca 2C o sensitivity per se as an extracellular mutation might, mutation of CASR T888 modulates receptor-induced signaling, preventing CASR-mediated Ca 2C i mobilization when phosphorylated (as mimicked by CASR T888D ) but permitting sustained CASR-mediated Ca 2C i mobilization when phosphorylation is prevented as in the case of CASR T888A in vitro (12) (13) (14) (15) or CASR T888M in vivo as reported in this study.
As previous studies on the significance of T888 for the control of CASR signaling were conducted using heterologous CASR expression in HEK-293 cells, it has been uncertain whether the CASR T888 residue exerts a critical function in vivo. Herein, we describe the clinical consequence of CASR T888 mutation in humans. As predicted by the in vitro studies, we found that CASR T888M is a gain-of-function mutation in vivo, resulting in ADH featuring inappropriately suppressed serum PTH levels, hypercalciuria, and hypocalcemia. To our knowledge, this is the first clinical case report of a mutation disrupting T888 phosphorylation. It confirms the importance of T888 in CASR function and also supports the current model for its role in CASR signaling. Live-cell imaging reveals that stimulation of the wt-CASR elicits Ca 2C i oscillations (29) (30) (31) (32) in a PKCsensitive manner, with PKC activation reducing the frequency of Ca 2C i oscillations (30, 31) . This suggests that CASR-mediated Ca 2C i oscillations result from negative feedback provided by PKC-mediated phosphorylation at T888, producing dynamic phosphorylation and dephosphorylation of CASR T888 (31) . In addition, we show here for the first time that downstream ERK phosphorylation is affected similar to Ca 2C i mobilization by CASR T888 mutation, with CASR T888M exhibiting greater Ca 2C o sensitivity ( Fig. 4 ) but without increasing cell surface expression of a FLAG-tagged receptor.
Recently, the use of a phospho-specific antibody against an epitope that included the phospho form of CASR T888 demonstrated PKC-mediated phosphorylation of the mature CASR in response to receptor activation, leading to feedback phosphorylation of CASR T888 (12 2 ) similar to that reported previously for CASR T888A (8) . We have also recently shown that the pattern of CASR-elicited Ca 2C i mobilization is dependent on receptor-stimulated dephosphorylation of CASR T888 , as it permits either the next Ca 2C i oscillation or even a sustained response (15) . In the light of these previous in vitro data, the current clinical study indicates that loss of the CASR T888 phosphorylation site via a T to M mutation results in gain-of-function at the level of the parathyroid gland and in turn, a significant disturbance of whole body calcium homeostasis. Furthermore, it is consistent with the presence of some degree of basal phosphorylation of the wt-CASR by PKC in vivo, which tonically suppresses the activity of the receptor under normocalcemic conditions. Loss of the capacity of PKC to phosphorylate CASR T888M should remove this inhibitory action, thereby increasing the activity of the mutant CASR and producing the biochemical phenotype of ADH.
Interestingly, 1,25(OH) 2 D was initially elevated in the index case, but was normal in his father. The conversion of 25OHD to its active metabolite 1,25(OH) 2 D is mediated by 1a-hydroxylase, a crucial regulatory enzyme of predominantly renal origin. Hypocalcemia stimulates renal 1a -hydroxylase activity independently of PTH and hypophosphatemia (33) , and although the CASR is expressed in renal proximal tubule cells (34) , it is not yet clear whether it mediates the effect of low serum Ca 2C o concentration on 1a-hydroxylase.
The current findings point either to the possibility of a CASR-independent mechanism or to a CASR signaling pathway whose sensitivity to serum Ca 2C o concentration is not enhanced by the T888M mutation.
In conclusion, we have described a family with ADH due to a novel CASR mutation, T888M. This case provides the first reported genotype-phenotype correlation of a mutation at this site, confirms previous in vitro findings that identified T888 as an important phosphorylation site in the CASR, and supports the current model for its role in CASR-mediated intracellular signaling.
